Atrium Therapeutics, Inc. (RNA)
NMS · Healthcare · Biotechnology
$12.37
-0.48%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$222.3M
P/S (TTM)
8.9x
Exchange
NMS
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2024-12-31 | 2025-03-31 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 3.0M | 1.6M | 859K | 19.6M |
| Operating Income | -44.2M | -7.5M | -48.0M | -17.3M |
| Net Income | -46.2M | -7.4M | -48.1M | -16.6M |
| Diluted EPS | $nan | $-0.44 | $nan | $-0.97 |
Annual Financials
| Metric | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | 9.8M | 10.9M | 18.6M |
| Operating Income | -6.4M | -13.2M | -76.8M |
| Net Income | -6.4M | -25.1M | -76.7M |
| Diluted EPS | $-0.37 | $-1.47 | $-4.48 |